<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657943</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2007-006665-33</org_study_id>
    <nct_id>NCT00657943</nct_id>
  </id_info>
  <brief_title>The Copenhagen Insulin and Metformin Therapy Trial</brief_title>
  <acronym>CIMT</acronym>
  <official_title>The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Frederiksberg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 Diabetes Mellitus patients (T2DM) have an increased mortality rate due to
      macrovascular disease. The primary objective of the study is to evaluate the effect of an
      18-month treatment with metformin versus placebo in combination with one of three insulin
      analogue regimens following a treat-to-target principle. The primary outcome measure is
      change in wall thickness of the carotic arteries(CIMT)measured by ultrasound. A total of 900
      patients with T2DM and HbA1c above 7.5% will be included.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Carotid intima media thickness</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">415</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Atherosclerosis</condition>
  <condition>Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>1M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin + Levemir x1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Levemir x1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin + NovoMix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + NovoMix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin + 4x therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + 4x therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>metformin tablets 2 g x 2</description>
    <arm_group_label>1M</arm_group_label>
    <arm_group_label>2M</arm_group_label>
    <arm_group_label>3M</arm_group_label>
    <other_name>glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
    <description>insulin as requested</description>
    <arm_group_label>1M</arm_group_label>
    <arm_group_label>1P</arm_group_label>
    <arm_group_label>3M</arm_group_label>
    <arm_group_label>3P</arm_group_label>
    <other_name>Levemir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart + insulin aspart protamin</intervention_name>
    <description>insulin as requested</description>
    <arm_group_label>2M</arm_group_label>
    <arm_group_label>2P</arm_group_label>
    <other_name>novomix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <description>insulin as requested</description>
    <arm_group_label>3M</arm_group_label>
    <arm_group_label>3P</arm_group_label>
    <other_name>NovoRapid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females over 30 years of age

          -  Type 2 diabetes

          -  Body mass index (BMI): 25.0-39.9 kg/m2

          -  HbA1c above 7.5 %

          -  Antidiabetic tablet-treatment during 1 year minimum AND / OR

          -  Insulin treatment during a minimum of 3 months

          -  Negative pregnancy test

          -  Signed, informed consent

        Exclusion Criteria:

          -  MI, coronary revascularization, TCI,or apoplexy within the last 3 months

          -  TCI with verified stenosis of above 70%

          -  Heart failure (NYHA class III or IV)

          -  Former cancer patient, unless disease-free period of more than 5 years

          -  estimated creatinine clearance &lt; 60 ml/min Liver disease

          -  Alcohol abuse

          -  Drug abuse

          -  Retinopathy with on-going laser treatment at start of study

          -  Other acute or chronic serious disease leading to hypoxia

          -  Pregnant or breastfeeding women

          -  Women of child-bearing potential, not using contraceptives

          -  Allergy to medication used in the study

          -  Incapable of understanding the nature of the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Almdal, MD DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederiksberg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Sygehus</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2830</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillerod Sygehus</name>
      <address>
        <city>Hillerod</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KÃ¸ge Sygehus</name>
      <address>
        <city>Koge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>February 2, 2014</last_update_submitted>
  <last_update_submitted_qc>February 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center</investigator_affiliation>
    <investigator_full_name>Lise Tarnow</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>carotid</keyword>
  <keyword>intima</keyword>
  <keyword>media</keyword>
  <keyword>thickness</keyword>
  <keyword>insulin</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

